![](https://tracker.live.rns-distribution.com/track.live-rns/4235104_75d1671758db0ed18eba2dbba83793b2.png)
10 January 2022
Nuformix plc
("Nuformix" or the "the Company")
Director/PDMR Shareholding
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that today the Company received notice that Dr Alastair Riddell purchased 400,000 ordinary shares of 0.1 pence each ("Ordinary Shares") at a price of 1.175 pence per share on 10 January 2022.
- Ends -
Nuformix plc | via Walbrook | ||||
Dr Alastair Riddell, Executive Chairman | | ||||
| | ||||
| | ||||
Allenby Capital Limited |
+44 (0) 20 3328 5656 | ||||
Nick Athanas / George Payne (Corporate Finance) | | ||||
Stefano Aquilino / Matt Butlin (Sales and Corporate Broking) | | ||||
| | ||||
Walbrook PR |
nuformix@walbrookpr.com or +44 (0)20 7933 8780 | ||||
Anna Dunphy / Phillip Marriage | Tel: +44 (0)7876 741 001 / +44 (0)7867 984 082 | ||||
| | | | | |
Enquiries:
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||
a)
| Name
| Dr Alastair Riddell | ||||
2
| Reason for the notification
| |||||
a)
| Position/status
| PDMR - Executive Chairman | ||||
b)
| Initial notification /Amendment
| Initial notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||
a)
| Name
| Nuformix plc | ||||
b)
| LEI
| 2138003XG3H3I2J3BJ24 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
a)
| Description of the financial instrument, type of instrument
Identification code
| Ordinary Shares of nominal value 0.1 pence each
GB00BYW79Y38 | ||||
b)
| Nature of the transaction
| Purchase of Ordinary Shares | ||||
c)
| Price(s) and volume(s)
|
| ||||
d)
| Aggregated information
- Aggregated volume
- Price
- Total |
400,000
1.175p
£4,700.00 | ||||
e)
| Date of the transaction
| 10 January 2022 | ||||
f)
| Place of the transaction
| London Stock Exchange, Main Market |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.